Zobrazeno 1 - 10
of 1 712
pro vyhledávání: '"ribociclib"'
Autor:
Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5722-5729 (2024)
Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact
Externí odkaz:
https://doaj.org/article/a433ba64f8604e4fafa1869340c79037
Autor:
Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 13, Pp 501-512 (2024)
Hikmat Abdel-Razeq,1,2 Baha Sharaf,1 Suhaib Khater,1 Huda Jafar Baidoun,2 Hira Bani Hani,1 Ayat Taqash,3 Osama El Khatib,1 Sarah Edaily,1 Mahmoud Abunasser,1 Faris Tamimi,1 Yosra Nabeel Al-Masri,1 Tamer Moh’d Waleed Al-Batsh,1 Anas Zayed,1 Tala Gha
Externí odkaz:
https://doaj.org/article/a11cfe5e6ffa41b2b2eca6ea7b3bc8f7
Autor:
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhib
Externí odkaz:
https://doaj.org/article/5b0a3d9bcc4b42bca28dd69de26ddc68
Autor:
Po-Jen Chen, Shun-Hua Chen, Yu-Li Chen, Yi-Hsuan Wang, Cheng-Yu Lin, Chun-Hong Chen, Yung-Fong Tsai, Tsong-Long Hwang
Publikováno v:
Journal of Advanced Research, Vol 62, Iss , Pp 229-243 (2024)
Introduction: Overwhelming neutrophil activation and oxidative stress significantly contribute to acute respiratory distress syndrome (ARDS) pathogenesis. However, the potential of repurposing ribociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) in
Externí odkaz:
https://doaj.org/article/253e57a5843748d2a16b88013cc43780
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 182-189 (2024)
The classification of breast cancer (BC) by immunohistochemical phenotypes is widely used in routine clinical practice. However, the genetic profile of the tumor does not always correspond to the pathomorphological one, which can significantly affect
Externí odkaz:
https://doaj.org/article/9bd059acb1804b48b14f790646bef706
Autor:
A. A. Alsarhan, A. S. Khwaldeh, J. D. Al-Shawabkeh, A. A Shoiab, R. Al-Shdefat, S. Al-Fawaeir, I. Yousef
Publikováno v:
Brazilian Journal of Biology, Vol 84 (2024)
Abstract A new approach to overcome or reduce these toxicities is by using antioxidants. Ribociclib, a CDK4/6 inhibitor used in the treatment of breast cancer, has been linked to hepatotoxicity and may contribute to the development of Hepatocellular
Externí odkaz:
https://doaj.org/article/9e8f935c27564541b17606b5b9e27bf1
Autor:
N. A. Avxentyev, I. I. Andreyashkina, E. V. Artamonova, L. V. Bolotina, E. I. Kovalenko, N. N. Sisigina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 1, Pp 64-81 (2024)
At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatm
Externí odkaz:
https://doaj.org/article/7c741cff50634683809ceae6e0a09add
Autor:
I. V. Kolyadina
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 1, Pp 89-103 (2024)
This review presents the evolution of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer, describes late relapse phenomenon, provides clinical rationale for escalation of treatment, analyzes the key stages of the metas
Externí odkaz:
https://doaj.org/article/9e0dc10a36ac41af969d515ba1adb06b
Autor:
Liudmila G. Zhukova, Larisa V. Bolotina, Victoria V. Dvornichenko, Natalia V. Fadeeva, Inna P. Ganshina, Katerina S. Grechukhina, Alfiya I. Hasanova, Nikolay V. Kislov, Igor Yu. Kudryavtsev, Alexey G. Manikhas, Natalia E. Musaeva, Alexandra A. Nizhegorodtseva, Olga E. Sadikova, Dina D. Sakaeva, Anton V. Snegovoy, Daniil L. Stroyakovskiy, Sergei A. Tjulandin, Ekaterina A. Trishkina, Liubov Iu. Vladimirova, Nikita M. Volkov, Yulia V. Kostalanova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 56-64 (2024)
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. The approval studies MONALEESA-2 and 7 demonstra
Externí odkaz:
https://doaj.org/article/38d513dc74f248e7bd74c0e83c57a19a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.